Sangamo Therapeutics Q3 EPS $(0.24) Beats $(0.34) Estimate, Sales $21.958M Beat $12.16M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.34) by 29.41 percent. This is a 84.62 percent decrease over losses of $(0.13) per share

Benzinga · 11/06/2019 21:53

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.34) by 29.41 percent. This is a 84.62 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $21.958 million which beat the analyst consensus estimate of $12.16 million by 80.58 percent. This is a 6.81 percent decrease over sales of $23.562 million the same period last year.